Literature DB >> 10954422

Biochemical characterization and localization of the dual specificity kinase CLK1.

H J Menegay1, M P Myers, F M Moeslein, G E Landreth.   

Abstract

CLK1 was one of the first identified dual specificity kinases and is the founding member of the 'LAMMER' family of kinases. We have established the substrate site specificity of CLK1. We report here that truncation of the N terminus of CLK1 resulted in a dramatic increase in CLK1 enzymatic activity, indicating that the N terminus acts as a negative regulatory domain. The N-terminal truncation resulted in a 45-fold increase in V(max), suggesting that this domain does not contain a pseudo-substrate motif, but may act to conformationally constrain the catalytic activity of CLK1. Tyrosine phosphorylation has been proposed to be critical for CLK1 activity, however, CLK1 activity was unaffected by exposure to tyrosine phosphatases. Treatment of CLK1 with the serine/threonine specific phosphatase PP2A, resulted in a 2- to 6-fold increase in enzymatic activity. Incubation of CLK1 with tyrosine phosphatases in combination with PP2A abolished CLK1 activity. These data suggest that CLK1 is regulated by three distinct mechanisms that serve to both positively and negatively regulate CLK1 activity. CLK1 activity is positively regulated by phosphorylation on either tyrosine residues or serine/threonine residues, and is negatively regulated by steric constraints mediated by the N-terminal domain, as well as, by phosphorylation on a subset of serine/threonine residues within the catalytic domain. CLK1 mRNA is expressed at low levels in all tissues and cell lines examined. The full-length and truncated splice forms are expressed at roughly equivalent levels in most tissues. The ratio of the two splice variants of CLK1 can be altered by treatment with cycloheximide. CLK1 protein expression is limited to a small subset of highly localized neuronal populations in the rat brain. Contrary to previous studies using overexpression systems, we show that CLK1 protein is primarily found in the cytoplasm of these cells, with only a small fraction localized to the nucleus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10954422     DOI: 10.1242/jcs.113.18.3241

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  18 in total

1.  Structural analysis of UBL5, a novel ubiquitin-like modifier.

Authors:  Teresa McNally; Qiulong Huang; Richard S Janis; Zhihong Liu; Edward T Olejniczak; Regina M Reilly
Journal:  Protein Sci       Date:  2003-07       Impact factor: 6.725

2.  Drosophila translational elongation factor-1gamma is modified in response to DOA kinase activity and is essential for cellular viability.

Authors:  Yujie Fan; Michael Schlierf; Ana Cuervo Gaspar; Catherine Dreux; Arlette Kpebe; Linda Chaney; Aurelie Mathieu; Christophe Hitte; Olivier Grémy; Emeline Sarot; Mark Horn; Yunlong Zhao; Terri Goss Kinzy; Leonard Rabinow
Journal:  Genetics       Date:  2009-10-19       Impact factor: 4.562

3.  LAMMER kinase contributes to genome stability in Ustilago maydis.

Authors:  Carmen de Sena-Tomás; Jeanette H Sutherland; Mira Milisavljevic; Dragana B Nikolic; José Pérez-Martín; Milorad Kojic; William K Holloman
Journal:  DNA Repair (Amst)       Date:  2015-06-19

4.  Optimization of Indazole-Based GSK-3 Inhibitors with Mitigated hERG Issue and In Vivo Activity in a Mood Disorder Model.

Authors:  Federica Prati; Rosa Buonfiglio; Guido Furlotti; Claudia Cavarischia; Giorgina Mangano; Rossella Picollo; Laura Oggianu; Anna di Matteo; Silvana Olivieri; Graziella Bovi; Pier Francesca Porceddu; Angelo Reggiani; Beatrice Garrone; Francesco Paolo Di Giorgio; Rosella Ombrato
Journal:  ACS Med Chem Lett       Date:  2020-03-24       Impact factor: 4.345

5.  Human biliverdin reductase: a member of the insulin receptor substrate family with serine/threonine/tyrosine kinase activity.

Authors:  Nicole Lerner-Marmarosh; Jenny Shen; Michael D Torno; Anatoliy Kravets; Zhenbo Hu; Mahin D Maines
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

6.  Regulation and substrate specificity of the SR protein kinase Clk/Sty.

Authors:  Jayendra Prasad; James L Manley
Journal:  Mol Cell Biol       Date:  2003-06       Impact factor: 4.272

7.  Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells.

Authors:  Ilmin Kwon; Siheng Xiang; Masato Kato; Leeju Wu; Pano Theodoropoulos; Tao Wang; Jiwoong Kim; Jonghyun Yun; Yang Xie; Steven L McKnight
Journal:  Science       Date:  2014-07-31       Impact factor: 47.728

8.  Nuclear protein kinase CLK1 uses a non-traditional docking mechanism to select physiological substrates.

Authors:  Malik M Keshwani; Kendra L Hailey; Brandon E Aubol; Laurent Fattet; Maria L McGlone; Patricia A Jennings; Joseph A Adams
Journal:  Biochem J       Date:  2015-10-06       Impact factor: 3.857

9.  A novel class of inhibitors that target SRSF10 and promote p53-mediated cytotoxicity on human colorectal cancer cells.

Authors:  Muhammad Sohail; Lulzim Shkreta; Johanne Toutant; Safwat Rabea; Jean-Philippe Babeu; Caroline Huard; Jasmin Coulombe-Huntington; Aurélie Delannoy; Morgane Placet; Sameh Geha; Fernand-Pierre Gendron; François Boudreau; Mike Tyers; David S Grierson; Benoit Chabot
Journal:  NAR Cancer       Date:  2021-05-25

10.  Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion.

Authors:  Yuying Liu; LaShardai Conaway; Jennifer Rutherford Bethard; Adnan M Al-Ayoubi; Amber Thompson Bradley; Hui Zheng; Scott A Weed; Scott T Eblen
Journal:  Nucleic Acids Res       Date:  2013-03-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.